AGC Biologics and Repair Biotechnologies Partner on Novel mRNA Therapeutic to Combat the Leading Cause of Human Mortality
AGC Biologics is manufacturing an mRNA therapy for Repair Biotechnologies to tackle one of the world’s most persistent health challenges and cause of mortality.
Circular Genomics to Unveil New Data Highlighting Circular RNAs as a Transformative New Class of Blood-Based Biomarkers for Alzheimer’s Disease at CTAD 2025
New clinical data highlights circular RNAs (circRNAs) as a novel, non-invasive blood biomarker platform for the early detection of Alzheimer’s Disease (AD). The research demonstrates that circRNAs offer comprehensive insights into the multiple disrupted disease pathways central to AD’s biology and pathology.
LifeNet Health Honors Recovery Partners with 2025 Excellence Awards
VIRGINIA BEACH, Va., Nov. 5, 2025 /PRNewswire/ — LifeNet Health proudly announces the recipients of its 2025 Partnership Excellence Awards, celebrating the extraordinary individuals and teams whose expertise and dedication transform tissue donations into lifesaving and life-enhancing gifts.
Alabama Genomic Health Initiative reaches 10,000-participant mark, a genomic medicine milestone for Alabama
More than 10,000 Alabamians have received genetic testing that could change the course of their health through the Alabama Genomic Health Initiative.
Broad Clinical Labs Sets New GUINNESS WORLD RECORDS™ Title for Fastest DNA Sequencing Technique
BOSTON, Oct. 16, 2025 /PRNewswire/ — Broad Clinical Labs (BCL), in collaboration with Roche Sequencing Solutions and Boston Children’s Hospital, today announced official recognition by Guinness World Records for achieving the fastest DNA sequencing technique to date.
Ellis Bio and UChicago Announce Breakthrough Ultra-Mild Bisulfite Sequencing Technology
NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present insights from its enLIGHTEN™ Discovery Platform, and additional data from the CAN-2409 (aglatimagene besadenovec) program in non-small cell lung cancer (NSCLC), through two accepted poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland.
PhenoVista Biosciences and Carolina Molecular Announce Partnership to Extend Multi-omic Data Access to Clients
SAN DIEGO, CA – September 11, 2025 – PhenoVista Biosciences and Carolina Molecular announce a partnership to combine their complementary CRO service capabilities to expand client access to broader multi-omic data.
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the Company will present insights from its enLIGHTEN™ Discovery Platform, and additional data from the CAN-2409 (aglatimagene besadenovec) program in non-small cell lung cancer (NSCLC), through two accepted poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Anniversary Annual Meeting, taking place November 5-9, 2025 in National Harbor, Maryland.
Promega and Watchmaker Genomics Announce Strategic Partnership to Advance Molecular Analysis with Next-Generation Reverse Transcriptase
Madison, WI and Boulder, CO – Promega Corporation has entered a strategic partnership with Watchmaker Genomics to license a novel engineered reverse transcriptase. Designed for enhanced accuracy and sensitivity in RNA analysis, the enzyme will enhance Promega capabilities to manufacture and deliver both catalog and customized solutions for clinical, applied and pharmaceutical molecular applications.
Twist Bioscience Collaborates with Synthetic Design Lab
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Sep. 2, 2025– Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation therapeutics company, Synthetic Design Lab (SDL).